Lead sponsor
Lumos Pharma
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of November 5, 2026.
1
Trials led
1
Ongoing
202
Total enrollment
0
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Trials by status
Not yet recruiting
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese AdultsBMI ≥30Ph 2Not yet recruiting202